The Massachusetts Institute of Technology (MIT) has launched Pandemic Response CoLab with the goal of bringing together innovators from around the globe to solve problems associated with COVID-19.
Carmine Therapeutics has signed a research collaboration agreement with Takeda Pharmaceutical to develop gene therapies for rare diseases.
Hoth Therapeutics has inked a sponsored research agreement with Virginia Commonwealth University (VCU) for a potential peptide COVID-19 treatment.
Avantor is increasing its investment in bioprocessing infrastructure by expanding its innovation center in Bridgewater, NJ.
AGC Biologics is expanding its plasmid DNA Center of Excellence in Heidelberg, Germany, to meet the need for process development and manufacturing of plasmid DNA.
Ajinomoto Bio-Pharma Services launched Ajility, a flexible drug product manufacturing platform for vaccines and therapies.
Marker Therapeutics plans to establish a new current good manufacturing practice manufacturing facility in Houston to support clinical development of multiantigen targeted-specific T-cell therapies.
ImmunoPrecise Antibodies has identified several lead candidate antibodies with high neutralizing activity in vitro that are being manufactured for further testing and possible inclusion in the company's PolyTope monoclonal antibody therapy against COVID-19.
Biocare Medical has formed a strategic partnership with Bethyl Laboratories to develop targeted antibodies for cancer research.
RevImmune has launched a phase II clinical trial of CYT107 immune therapy for treatment of COVID-19 and is preparing to expand to the U.S.